Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy of systemic vasculitis

L H Calabrese1

  • 1Department of Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

Neurologic Clinics
|March 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

Pathogens & immunity·2021
Same author

Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.

Clinical and experimental dermatology·2018
Same author

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

RMD open·2017
Same author

Menstrual Abnormalities, Nutritional Patterns, and Body Composition in Female Classical Ballet Dancers.

The Physician and sportsmedicine·2016
Same author

AIDS and Athletes.

The Physician and sportsmedicine·2016
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Systemic vasculitides are complex immune disorders. Current treatments using glucocorticoids may cause significant toxicity, prompting research into safer, more specific therapies for better disease control and reduced side effects.

Area of Science:

  • Immunology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic vasculitides are a heterogeneous group of immune-mediated disorders.
  • Standard treatment involves glucocorticoids, often without cytotoxic agents.
  • Long-term follow-up reveals significant treatment-related toxicity.

Purpose of the Study:

  • To review current therapeutic strategies for systemic vasculitides.
  • To highlight the risks of treatment-related toxicity.
  • To discuss the need for novel therapeutic agents.

Main Methods:

  • Review of existing literature on systemic vasculitides treatment.
  • Analysis of long-term follow-up data regarding treatment toxicity.
  • Examination of emerging therapeutic agents.

Related Experiment Videos

Main Results:

  • Standard glucocorticoid therapy can lead to alarming treatment-related toxicity.
  • Current regimens aim to balance disease control with toxicity minimization.
  • New agents with improved specificity and reduced toxicity are under investigation.

Conclusions:

  • There is a critical need to address treatment-related toxicity in systemic vasculitides.
  • Development of targeted therapies is essential for improved patient outcomes.
  • Future research focuses on agents with greater disease specificity and lower toxicity.